Astria Therapeutics Inc Cash Flow Conversion Efficiency
Astria Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Astria Therapeutics Inc (ATXS) has a cash flow conversion efficiency ratio of -0.138x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.30 Million) by net assets ($233.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Astria Therapeutics Inc (2012–2024)
Cash flow conversion efficiency of Astria Therapeutics Inc from 2012 to 2024. This chart illustrates how Astria Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Astria Therapeutics Inc stock quote for real-time trading data and today's change.
Astria Therapeutics Inc Cash Flow Conversion Ratio Explained
Astria Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Astria Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Astria Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Astria Therapeutics Inc (ATXS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
-0.002x |
|
Beijing Philisense Tech
SHE:300287
|
-0.024x |
|
Shanghai Pudong Road & Bridge Construction Co Ltd
SHG:600284
|
0.035x |
|
Molinos Agro SA
BA:MOLA
|
-1.906x |
|
ProFrac Holding Corp.
NASDAQ:ACDC
|
0.001x |
|
HELL.UNSP.ADR A1 DL-0001
F:1MO
|
0.050x |
|
Cemindo Gemilang Tbk PT
JK:CMNT
|
0.068x |
|
Beijing E Hualu Info Tech
SHE:300212
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Astria Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Astria Therapeutics Inc from 2012 to 2024. Review financial agility of Astria Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $319.26 Million | $-81.21 Million | -0.254x | +9.65% |
| 2023-12-31 | $243.12 Million | $-68.44 Million | -0.282x | -43.06% |
| 2022-12-31 | $221.22 Million | $-43.53 Million | -0.197x | +20.17% |
| 2021-12-31 | $122.31 Million | $-30.15 Million | -0.247x | +69.14% |
| 2020-12-31 | $40.67 Million | $-32.48 Million | -0.799x | -7.39% |
| 2019-12-31 | $35.72 Million | $-26.57 Million | -0.744x | -10.76% |
| 2018-12-31 | $34.94 Million | $-23.46 Million | -0.672x | +70.49% |
| 2017-12-31 | $11.79 Million | $-26.84 Million | -2.276x | -101.45% |
| 2016-12-31 | $29.09 Million | $-32.86 Million | -1.130x | -91.46% |
| 2015-12-31 | $50.49 Million | $-29.79 Million | -0.590x | -311.17% |
| 2014-12-31 | $-73.05 Million | $-20.41 Million | 0.279x | -10.91% |
| 2013-12-31 | $-52.18 Million | $-16.37 Million | 0.314x | +108.63% |
| 2012-12-31 | $4.29K | $-15.58K | -3.634x | -- |
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more